Flecainide in the Wolff-Parkinson-White syndrome
Identifieur interne : 000155 ( Main/Corpus ); précédent : 000154; suivant : 000156Flecainide in the Wolff-Parkinson-White syndrome
Auteurs : Ian CrozierSource :
- The American Journal of Cardiology [ 0002-9149 ] ; 1992.
Abstract
The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.
Url:
DOI: 10.1016/0002-9149(92)91074-E
Links to Exploration step
ISTEX:6CE97C7DC3D05682871620BECA3DB2EB9D710005Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Flecainide in the Wolff-Parkinson-White syndrome</title><author><name sortKey="Crozier, Ian" sort="Crozier, Ian" uniqKey="Crozier I" first="Ian" last="Crozier">Ian Crozier</name><affiliation><mods:affiliation>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6CE97C7DC3D05682871620BECA3DB2EB9D710005</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0002-9149(92)91074-E</idno><idno type="url">https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000155</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Flecainide in the Wolff-Parkinson-White syndrome</title><author><name sortKey="Crozier, Ian" sort="Crozier, Ian" uniqKey="Crozier I" first="Ian" last="Crozier">Ian Crozier</name><affiliation><mods:affiliation>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="ISSN">0002-9149</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="A26">A26</biblScope><biblScope unit="page" to="A32">A32</biblScope></imprint><idno type="ISSN">0002-9149</idno></series><idno type="istex">6CE97C7DC3D05682871620BECA3DB2EB9D710005</idno><idno type="DOI">10.1016/0002-9149(92)91074-E</idno><idno type="PII">0002-9149(92)91074-E</idno><idno type="ArticleID">9291074E</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-9149</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Ian Crozier MD</name><affiliations><json:string>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</json:string></affiliations></json:item></author><articleId><json:string>9291074E</json:string></articleId><language><json:string>eng</json:string></language><abstract>The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.</abstract><qualityIndicators><score>6.143</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1326</abstractCharCount><pdfWordCount>4079</pdfWordCount><pdfCharCount>29641</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>172</abstractWordCount></qualityIndicators><title>Flecainide in the Wolff-Parkinson-White syndrome</title><pii><json:string>0002-9149(92)91074-E</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>34</volume><pages><first>775</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Fed Proc</title></serie><host><volume>70</volume><pii><json:string>S0002-9149(00)X0948-4</json:string></pii><editor><json:item><name>Robert J. Myerburg</name></json:item><json:item><name>MD</name></json:item><json:item><name>Pedro Brugada</name></json:item><json:item><name>MD</name></json:item></editor><pages><last>A32</last><first>A26</first></pages><conference><json:item><name>A Symposium: Use of Flecainide for the Treatment of Supraventricular Arrhythmias, Amsterdam, The Netherlands 19910817</name></json:item></conference><issn><json:string>0002-9149</json:string></issn><issue>5</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>The American Journal of Cardiology</title><publicationDate>1992</publicationDate></host><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1016/0002-9149(92)91074-E</json:string></doi><id>6CE97C7DC3D05682871620BECA3DB2EB9D710005</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Flecainide in the Wolff-Parkinson-White syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1992</date></publicationStmt><notesStmt><note>This study was supported by a grant from 3M Pharmaceuticals, St. Paul, Minnesota.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Flecainide in the Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Ian</forename><surname>Crozier</surname></persName><roleName type="degree">MD</roleName><note type="biography">Address for reprints: Ian Crozier, MD, Department of Cardiology, The Princess Margaret Hospital, Christchurch 2, New Zealand.</note><affiliation>Address for reprints: Ian Crozier, MD, Department of Cardiology, The Princess Margaret Hospital, Christchurch 2, New Zealand.</affiliation><affiliation>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</affiliation></author></analytic><monogr><title level="j">The American Journal of Cardiology</title><title level="j" type="abbrev">AJC</title><idno type="pISSN">0002-9149</idno><idno type="PII">S0002-9149(00)X0948-4</idno><meeting><addName>A Symposium: Use of Flecainide for the Treatment of Supraventricular Arrhythmias, Amsterdam, The Netherlands</addName><date>19910817</date></meeting><editor><persName>Robert J. Myerburg</persName></editor><editor><persName>MD</persName></editor><editor><persName>Pedro Brugada</persName></editor><editor><persName>MD</persName></editor><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992"></date><biblScope unit="volume">70</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="A26">A26</biblScope><biblScope unit="page" to="A32">A32</biblScope></imprint></monogr><idno type="istex">6CE97C7DC3D05682871620BECA3DB2EB9D710005</idno><idno type="DOI">10.1016/0002-9149(92)91074-E</idno><idno type="PII">0002-9149(92)91074-E</idno><idno type="ArticleID">9291074E</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.</p></abstract></profileDesc><revisionDesc><change when="1992">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>AJC</jid><aid>9291074E</aid><ce:pii>0002-9149(92)91074-E</ce:pii><ce:doi>10.1016/0002-9149(92)91074-E</ce:doi><ce:copyright type="unknown" year="1992"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>This study was supported by a grant from 3M Pharmaceuticals, St. Paul, Minnesota.</ce:note-para></ce:article-footnote><ce:title>Flecainide in the Wolff-Parkinson-White syndrome</ce:title><ce:author-group><ce:author><ce:given-name>Ian</ce:given-name><ce:surname>Crozier</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address for reprints: Ian Crozier, MD, Department of Cardiology, The Princess Margaret Hospital, Christchurch 2, New Zealand.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.</ce:simple-para><ce:simple-para view="all" id="simple-para.0015">Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Flecainide in the Wolff-Parkinson-White syndrome</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Flecainide in the Wolff-Parkinson-White syndrome</title></titleInfo><name type="personal"><namePart type="given">Ian</namePart><namePart type="family">Crozier</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Department of Cardiology, The Princess Margaret Hospital, Christchurch, New Zealand</affiliation><description>Address for reprints: Ian Crozier, MD, Department of Cardiology, The Princess Margaret Hospital, Christchurch 2, New Zealand.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The effects of flecainide on electrophysiologic parameters and arrhythmias in the Wolff-Parkinson-White syndrome were reviewed. Acute administration of flecainide blocks conduction across the accessory pathway in the anterograde direction in 40% and in the retrograde direction in 50% of cases and markedly prolongs refractoriness in the remaining cases. Flecainide has a lesser effect on refractoriness of the His-Purkinje system, atrium, ventricle, and atrioventricular node.Flecainide terminates atrioventricular tachycardia in >80% of cases when given intravenously, and oral therapy prevents clinical recurrences in >60% of cases, but may occasionally result in incessant tachycardia. Long-term efficacy is predicted by abolition of conduction across the accessory pathway or prevention of tachycardia induction at acute electrophysiologic testing. Concomitant administration of a β-adrenoreceptor blocker results in greater long-term efficacy. Administered during preexcited atrial fibrillation, flecainide consistently slows the ventricular response and converts the majority of cases to sinus rhythm. Serious ventricular proarrhythmia is seen almost exclusively in patients with structural cardiac disease. Flecainide is a useful drug for the acute and chronic control of tachycardia in Wolff-Parkinson-White syndrome.</abstract><note>This study was supported by a grant from 3M Pharmaceuticals, St. Paul, Minnesota.</note><relatedItem type="host"><titleInfo><title>The American Journal of Cardiology</title></titleInfo><titleInfo type="abbreviated"><title>AJC</title></titleInfo><name type="conference"><namePart>A Symposium: Use of Flecainide for the Treatment of Supraventricular Arrhythmias, Amsterdam, The Netherlands</namePart><namePart type="date">19910817</namePart></name><name type="personal"><namePart>Robert J. Myerburg</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>MD</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Pedro Brugada</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>MD</namePart><role><roleTerm type="text">editor</roleTerm></role></name><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19920820</dateIssued></originInfo><identifier type="ISSN">0002-9149</identifier><identifier type="PII">S0002-9149(00)X0948-4</identifier><part><date>19920820</date><detail type="issue"><title>A Symposium: Use of Flecainide for the Treatment of Supraventricular Arrhythmias, Amsterdam, The Netherlands</title></detail><detail type="volume"><number>70</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue pages"><start>A1</start><end>A74</end></extent><extent unit="pages"><start>A26</start><end>A32</end></extent></part></relatedItem><identifier type="istex">6CE97C7DC3D05682871620BECA3DB2EB9D710005</identifier><identifier type="DOI">10.1016/0002-9149(92)91074-E</identifier><identifier type="PII">0002-9149(92)91074-E</identifier><identifier type="ArticleID">9291074E</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/6CE97C7DC3D05682871620BECA3DB2EB9D710005/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><analytic><title level="a" type="main">Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia</title><author><persName><forename type="middle">L</forename><surname>Wolff</surname></persName></author><author><persName><forename type="middle">J</forename><surname>Parkinson</surname></persName></author><author><persName><surname>White</surname></persName></author></analytic><monogr><title level="j">Am Heart J</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page" from="685" to="704"></biblScope><date type="published" when="1930"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The surgical treatment of Wolff-Parkinson-White syndrome: evolution of improved methods for identification and interruption of the Kent bundle</title><author><persName><surname>Scaly</surname></persName></author><author><persName><surname>Wc</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author><author><persName><surname>Wallace</surname></persName></author><author><persName><surname>Ag</surname></persName></author></analytic><monogr><title level="j">Anrt Thorac Surg</title><imprint><biblScope unit="volume">22</biblScope><biblScope unit="page" from="443" to="457"></biblScope><date type="published" when="1976"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">High frequency alternat-ing current ablation of an accessory pathway in humans</title><author><persName><forename type="middle">M</forename><surname>Borggrefe</surname></persName></author><author><persName><forename type="middle">T</forename><surname>Budde</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Podczeck</surname></persName></author><author><persName><surname>Breithard</surname></persName></author></analytic><monogr><title level="j">JAm Coil Car&</title><imprint><biblScope unit="volume">10</biblScope><biblScope unit="page" from="576" to="582"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ventricular fibrillation in the Wolff-Parkinson-White syndrome</title><author><persName><surname>Klein Gj</surname></persName></author><author><persName><forename type="middle">Tm</forename><surname>Bashore</surname></persName></author><author><persName><forename type="middle">Td</forename><surname>Sellers</surname></persName></author><author><persName><surname>Pritchett</surname></persName></author><author><persName><surname>Elc</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author></analytic><monogr><title level="j">N Engl J Med</title><imprint><biblScope unit="volume">301</biblScope><biblScope unit="page" from="108" to="1085"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syn-drome</title><author><persName><forename type="first">Wellens</forename><forename type="middle">Hj</forename><surname>Durrer</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">47</biblScope><biblScope unit="page" from="1229" to="1233"></biblScope><date type="published" when="1973"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome</title><author><persName><surname>Harper Rw</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Whitford</surname></persName></author><author><persName><forename type="middle">K</forename><surname>Middlebrook</surname></persName></author><author><persName><forename type="first">Anderson</forename><forename type="middle">J S</forename><surname>Federman</surname></persName></author><author><persName><surname>Pitt</surname></persName></author></analytic><monogr><title level="j">Am .I Cardiol</title><imprint><biblScope unit="volume">50</biblScope><biblScope unit="page" from="1323" to="1330"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic properties of flecainide acetate</title><author><persName><forename type="first">Estes</forename><forename type="middle">Nam H</forename><surname>Garan</surname></persName></author><author><persName><surname>Jn</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">53</biblScope><biblScope unit="page" from="2" to="29"></biblScope><date type="published" when="1984"></date></imprint></monogr><note>suppl. B</note></biblStruct><biblStruct><analytic><title level="a" type="main">Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in men</title><author><persName><surname>Hellestrand Kj</surname></persName></author><author><persName><forename type="first">Nathan</forename><forename type="middle">Rs Aw</forename><surname>Bexton</surname></persName></author><author><persName><surname>Spurrell Rat</surname></persName></author><author><persName><surname>Camm</surname></persName></author><author><persName><surname>Aj</surname></persName></author></analytic><monogr><title level="j">Br Heart J</title><imprint><biblScope unit="volume">48</biblScope><biblScope unit="page" from="14" to="148"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction Am J Cardiol1982:50: lO9MO94. M. Olsson SB, Edvardsson N. Clinical electrophysiologic study of antiarrhyth-mic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracar-diac monophasic action potentials with programmed stimulation</title><author><persName><surname>Vik-Mo H</surname></persName></author><author><persName><forename type="first">Buss</forename><forename type="middle">H J</forename><surname>Ole-Jorgen</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Schlepper</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Berthold</surname></persName></author><author><persName><forename type="middle">V</forename><surname>Mitrovic</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Kramer</surname></persName></author><author><persName><surname>Wj</surname></persName></author></analytic><monogr><title level="j">Am Heart J</title><editor>864871. ll</editor><imprint><biblScope unit="volume">102</biblScope><date type="published" when="1981"></date></imprint></monogr><note>Effects. of flecainide on electrophysiological properties of accessory path-ways in the Wolff-Parkinson-White syndrome. Eur Heart J 19834347-353</note></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologische Effekte das neuen Antiarrhythmikums Flecainide (P 818) beim Menschen</title><author><persName><forename type="middle">L</forename><surname>Seipel</surname></persName></author><author><persName><surname>Abenroth Rr</surname></persName></author><author><persName><surname>Breithardt</surname></persName></author></analytic><monogr><title level="j">Z Kardiol</title><imprint><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><monogr><imprint><biblScope unit="page" from="70" to="524"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds</title><author><persName><surname>Hellestrand</surname></persName></author><author><persName><forename type="first">Nathan</forename><forename type="middle">Aw</forename><surname>Kj</surname></persName></author><author><persName><surname>Bexton Rs</surname></persName></author><author><persName><surname>Camm</surname></persName></author><author><persName><surname>Aj</surname></persName></author></analytic><monogr><title level="j">Am J</title><imprint><biblScope unit="volume">53</biblScope><biblScope unit="page" from="30" to="38"></biblScope><date type="published" when="1984"></date></imprint></monogr><note>suppl. B</note></biblStruct><biblStruct><analytic><title level="a" type="main">Treatment of paroxysmal supraventricular tachycar-dia with flecainide acetate</title><author><persName><forename type="first">Kim</forename><forename type="middle">R</forename><surname>Ss</surname></persName></author></analytic><monogr><title level="j">Am J</title><imprint><biblScope unit="volume">58</biblScope><biblScope unit="page" from="8" to="3"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Safety and efficacy of oral flecainide therapy in patients with atrioventricular reentrant tachycardia</title><author><persName><surname>Cockrell Jl</surname></persName></author><author><persName><surname>Scheinman</surname></persName></author><author><persName><forename type="first">Titus</forename><forename type="middle">C</forename><surname>Mm</surname></persName></author><author><persName><forename type="middle">I</forename><surname>Hehny</surname></persName></author><author><persName><surname>Langberg</surname></persName></author><author><persName><surname>Jj</surname></persName></author><author><persName><surname>Lee</surname></persName></author><author><persName><surname>Griflin</surname></persName></author><author><persName><surname>Jc</surname></persName></author></analytic><monogr><title level="j">Ann ht Med</title><imprint><biblScope unit="volume">114</biblScope><biblScope unit="page" from="189" to="194"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia</title><author><persName><surname>Hoff Pi</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Tronstad</surname></persName></author><author><persName><forename type="middle">B</forename><surname>Oie</surname></persName></author><author><persName><surname>Ohm</surname></persName></author><author><persName><surname>Oj</surname></persName></author></analytic><monogr><title level="j">Am J</title><imprint><biblScope unit="volume">62</biblScope><biblScope unit="page" from="585" to="589"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects, efficacy and tolerance of class IC antiarrhythmic agents in Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Manolis</forename><surname>As</surname></persName></author><author><persName><forename type="middle">Dn</forename><surname>Salem</surname></persName></author><author><persName><surname>Nam</surname></persName></author></analytic><monogr><title level="j">Am J Cardioi</title><imprint><biblScope unit="volume">63</biblScope><biblScope unit="page" from="746" to="750"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syn-drome</title><author><persName><forename type="first">Manolis</forename><forename type="middle">As</forename><surname>Nam</surname></persName></author></analytic><monogr><title level="j">Am J</title><imprint><biblScope unit="volume">64</biblScope><biblScope unit="page" from="194" to="198"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysio-logic effects of isoproterenol in patients with atrioventricular reentrant tachycar-dia treated with flecainide</title><author><persName><forename type="middle">I</forename><surname>Helmy</surname></persName></author><author><persName><surname>Scheinman Mm</surname></persName></author><author><persName><forename type="middle">Jm</forename><surname>Herre</surname></persName></author><author><persName><forename type="middle">H</forename><surname>Sharkey</surname></persName></author><author><persName><surname>G&m</surname></persName></author><author><persName><surname>Jc</surname></persName></author></analytic><monogr><title level="j">JAm Coil Cardiol</title><imprint><biblScope unit="volume">16</biblScope><biblScope unit="page" from="1649" to="1655"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Antiarrhythmic and electrophysiologic actions of flecainide in animal models Some antiar-rhythmic actions of a new compound, R-818, in dogs and mice</title><author><persName><surname>Kvam Dc</surname></persName></author><author><persName><forename type="middle">Eh</forename><surname>Banitt</surname></persName></author><author><persName><forename type="first">Jr</forename><surname>Schmid</surname></persName></author><author><persName><surname>Schmid Jr</surname></persName></author><author><persName><surname>Seeback</surname></persName></author><author><persName><forename type="first">Henrie</forename><forename type="middle">Cl</forename><surname>Bd</surname></persName></author><author><persName><surname>Banitt Eh</surname></persName></author><author><persName><surname>Kvam</surname></persName></author><author><persName><surname>Dc</surname></persName></author></analytic><monogr><title level="j">Am J Cardioll984 Fed Proc Drugs</title><imprint><biblScope unit="volume">533429</biblScope><biblScope unit="issue">suppl4</biblScope><biblScope unit="page" from="22" to="257757"></biblScope><date type="published" when="1975"></date></imprint></monogr><note>suppl. B</note></biblStruct><biblStruct><analytic><title level="a" type="main">Long term use of flecainide in patients with supraventricular tachycardia</title><author><persName><forename type="first">Neuss</forename><forename type="middle">H</forename></persName></author></analytic><monogr><title level="j">Dnxgs</title><imprint><biblScope unit="volume">29</biblScope><biblScope unit="issue">suppl4</biblScope><biblScope unit="page" from="21" to="25"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">A study of the use of Aecainide acetate in the long-term management of cardiac arrhythmias</title><author><persName><surname>Wiseman Mn</surname></persName></author><author><persName><surname>Elstob Je</surname></persName></author><author><persName><surname>Camm</surname></persName></author><author><persName><surname>Aj</surname></persName></author><author><persName><surname>Nathan</surname></persName></author><author><persName><surname>Aw</surname></persName></author></analytic><monogr><title level="j">PACE</title><imprint><biblScope unit="volume">13</biblScope><biblScope unit="page" from="767" to="775"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Fredell PA Summary of efficacy and safety of Aecainide for supraventricular arrhythmias</title><author><persName><forename type="first">Anderson</forename><forename type="middle">Jl</forename><surname>Joliiette</surname></persName></author><author><persName><surname>Dm</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">62</biblScope><biblScope unit="page" from="62" to="66"></biblScope><date type="published" when="1988"></date></imprint></monogr><note>suppl. D</note></biblStruct><biblStruct><analytic><title level="a" type="main">Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias</title><author><persName><surname>Benditt Dg</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Durmigan</surname></persName></author><author><persName><forename type="middle">J</forename><surname>Buetikofer</surname></persName></author><author><persName><surname>Milstein</surname></persName></author></analytic><monogr><title level="j">Circ&z-fim</title><imprint><biblScope unit="volume">83</biblScope><biblScope unit="page" from="345" to="349"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atria1 fibrillation</title><author><persName><surname>Pritchett Elc</surname></persName></author><author><persName><surname>Datorre</surname></persName></author><author><persName><surname>Sd</surname></persName></author><author><persName><surname>Platt Ml</surname></persName></author><author><persName><surname>Mccarville</surname></persName></author><author><persName><surname>Se</surname></persName></author><author><persName><surname>Hougham</surname></persName></author><author><persName><surname>Aj</surname></persName></author></analytic><monogr><title level="j">JAm Co11 Cardiol</title><imprint><biblScope unit="volume">17</biblScope><biblScope unit="page" from="297" to="303"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome</title><author><persName><surname>Gossinger Hd</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Siostrzonek</surname></persName></author><author><persName><surname>Mosslacher</surname></persName></author></analytic><monogr><title level="j">Int J Cardioll990</title><imprint><biblScope unit="volume">26</biblScope><biblScope unit="page" from="380" to="382"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Proar-rhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Hem-t Treatment of atria1 tachyarrhythmias and preexcitation syndrome with flecainide acetate</title><author><persName><forename type="first">Nathan</forename><forename type="middle">Aw</forename><surname>Hellestrand Kj</surname></persName></author><author><persName><surname>Bexton Rs</surname></persName></author><author><persName><surname>Banim</surname></persName></author><author><persName><surname>So</surname></persName></author><author><persName><surname>Spurrell</surname></persName></author><author><persName><surname>Ss</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Smith</surname></persName></author></analytic><monogr><title level="j">J Am J Cardbl</title><imprint><biblScope unit="volume">10762</biblScope><biblScope unit="issue">33</biblScope><biblScope unit="page" from="222" to="22829"></biblScope><date type="published" when="1984"></date></imprint></monogr><note>suppl. D</note></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of drugs in the Wol%Parkinson-White syndrome</title><author><persName><forename type="first">Wellens</forename><forename type="middle">Hjj</forename><surname>Bar Fw</surname></persName></author><author><persName><surname>Dassen Wrm</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Brugada</surname></persName></author><author><persName><surname>Vanagt Eg</surname></persName></author><author><persName><surname>Farre</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">665669</biblScope><date type="published" when="000-1"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Intravenous flecainide acetate for supraventicular tachycar-dias</title><author><persName><forename type="first">Kj</forename><surname>Hellestrand</surname></persName></author></analytic><monogr><title level="j">Am J Cardi</title><imprint><biblScope unit="volume">62</biblScope><biblScope unit="page" from="1" to="22"></biblScope><date type="published" when="1988"></date></imprint></monogr><note>suppl. D</note></biblStruct><biblStruct><analytic><title level="a" type="main">Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Crijns</forename><forename type="middle">Hjgm P</forename><surname>Heijer</surname></persName></author><author><persName><surname>Wijk Lm</surname></persName></author><author><persName><surname>Lie</surname></persName></author><author><persName><surname>Ki</surname></persName></author></analytic><monogr><title level="j">Am Heart J</title><imprint><biblScope unit="volume">115</biblScope><biblScope unit="page" from="1317" to="1321"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Prevention of symptomatic recur-rences of paroxysmal atrial fibrillation in patients initially tolerating antiamhyth-mic therapy</title><author><persName><forename type="first">Anderson</forename><forename type="middle">Jl</forename></persName></author><author><persName><forename type="first">Gilbert</forename><forename type="middle">Em</forename><surname>Alpert Bl</surname></persName></author><author><persName><forename type="first">Waldo</forename><forename type="middle">Al</forename><surname>Henthorn Rw</surname></persName></author><author><persName><surname>Ak</surname></persName></author><author><persName><forename type="middle">Rw</forename><surname>Hawkinson</surname></persName></author><author><persName><surname>Pritchett</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">80</biblScope><biblScope unit="page" from="1557" to="1570"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Kent's fibers and the A-V pamspecific conduction through the upper connections of the bundle of His-Tawara</title><author><persName><forename type="first">I</forename><surname>Mahaim</surname></persName></author></analytic><monogr><title level="j">Am Heart J</title><imprint><biblScope unit="volume">33</biblScope><biblScope unit="page">651653</biblScope><date type="published" when="1941"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ventricular preexcitation due to anomalous nodo-ventricular pathways: report of 3 patients</title><author><persName><forename type="first">Ward</forename><forename type="middle">De</forename><surname>Camm Aj</surname></persName></author><author><persName><forename type="middle">Raj</forename><surname>Spurrell</surname></persName></author></analytic><monogr><title level="j">EurJ</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page" from="111" to="127"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Role of Mahaim fibers in cardiac arrhythmias in man</title><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><forename type="first">Benson</forename><forename type="middle">Dw</forename><surname>Jh</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Sterba</surname></persName></author><author><persName><surname>Grant</surname></persName></author><author><persName><surname>Ao</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">64</biblScope><biblScope unit="page" from="17" to="189"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres</title><author><persName><forename type="first">Davies</forename><forename type="middle">Dw</forename><surname>Lau Cp</surname></persName></author><author><persName><forename type="middle">D</forename><surname>Mehta</surname></persName></author><author><persName><forename type="middle">Dw</forename><surname>Ward</surname></persName></author><author><persName><surname>Camm</surname></persName></author><author><persName><surname>Aj</surname></persName></author></analytic><monogr><title level="j">Ew Heati J</title><imprint><biblScope unit="volume">8</biblScope><biblScope unit="page" from="832" to="839"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Conversion of supraventricular arrhythmias to sinus rhythm using flecainide</title><author><persName><surname>Goy Jj</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Crbic</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Humi</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Finci</surname></persName></author><author><persName><forename type="middle">R</forename><surname>Maendly</surname></persName></author><author><persName><forename type="first">J</forename><surname>Due</surname></persName></author><author><persName><surname>S&art</surname></persName></author></analytic><monogr><title level="j">Eur Heart J</title><imprint><biblScope unit="volume">6</biblScope><biblScope unit="page" from="51" to="524"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Efficacy and safety of flecainide acetate for atria1 tachycardia or fibrillation</title><author><persName><forename type="first">Rinkenberger</forename><forename type="middle">E Rl</forename><surname>Berm</surname></persName></author><author><persName><forename type="middle">Mk</forename><surname>Jeang</surname></persName></author><author><persName><forename type="first">Jenkins</forename><forename type="middle">Ah M</forename><surname>Dougherty</surname></persName></author><author><persName><surname>Cv</surname></persName></author></analytic><monogr><title level="j">Am J Cardi</title><imprint><biblScope unit="volume">59</biblScope><biblScope unit="page" from="1337" to="1341"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Flecatiide acetate in atria1 flutter and fibrillation; the arrhythmogenic effects</title><author><persName><forename type="middle">I</forename><surname>Sihm</surname></persName></author><author><persName><forename type="first">Rasmussen</forename><forename type="middle">Fa J</forename><surname>Hansen</surname></persName></author><author><persName><surname>Pedersen Ak</surname></persName></author><author><persName><surname>Thygesen</surname></persName></author></analytic><monogr><title level="j">Eur Heart J</title><imprint><biblScope unit="page" from="145" to="148"></biblScope><date type="published" when="199011"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation</title><author><persName><forename type="first">Rh</forename><surname>Fail</surname></persName></author></analytic><monogr><title level="j">Ann Intern Med</title><imprint><biblScope unit="volume">111</biblScope><biblScope unit="page" from="107" to="111"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Flecainide acetate for resistant arrhythmias in the young: efficacy and pharma-cokinetics</title><author><persName><forename type="middle">Jc</forename><surname>Peny</surname></persName></author><author><persName><forename type="middle">Rl</forename><surname>Mcquinn</surname></persName></author><author><persName><forename type="middle">Rt</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">C</forename><surname>Cothing</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Fredell</surname></persName></author><author><persName><surname>Carson</surname></persName></author></analytic><monogr><title level="j">JAm Coil</title><imprint><biblScope unit="volume">14</biblScope><biblScope unit="page" from="185" to="191"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects and clinical efficacy of tlecajnide in children with recurrent paroxysmal supraventricular tachycardia</title><author><persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Musto</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Onofrio</surname></persName></author><author><persName><forename type="middle">C</forename><surname>Cavallaro</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Must0</surname></persName></author><author><persName><surname>Creco</surname></persName></author></analytic><monogr><title level="j">Am J Cardbll988</title><imprint><biblScope unit="volume">62</biblScope><biblScope unit="page" from="229" to="233"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Use of flecainide acetate for refrac-tory junctional tachycardias in children with the Wolff-Parkinson-White syn-drome</title><author><persName><forename type="first">Ward</forename><forename type="middle">De</forename></persName></author><author><persName><forename type="first">Jones</forename><forename type="middle">S</forename><surname>Shineboume</surname></persName></author><author><persName><surname>Ea</surname></persName></author></analytic><monogr><title level="j">Am J</title><imprint><biblScope unit="volume">57</biblScope><biblScope unit="page" from="787" to="790"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">The response of pediatric arrhythmias to intrave-nous and oral flecainide</title><author><persName><forename type="first">Wren</forename><forename type="middle">C</forename><surname>Campbell</surname></persName></author></analytic><monogr><title level="j">Br Heart J</title><imprint><biblScope unit="volume">57</biblScope><biblScope unit="page" from="171" to="175"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Experience with flecainide for the treatment of cardiac arrhythmias in children</title><author><persName><forename type="first">Ladusans</forename><forename type="middle">Ka Ej E</forename><surname>Priestley</surname></persName></author><author><persName><surname>Holt</surname></persName></author><author><persName><forename type="first">Tynan</forename><forename type="middle">Mj</forename><surname>Dw</surname></persName></author><author><persName><forename type="first">Jones</forename><forename type="middle">Odh</forename><surname>Cnrq</surname></persName></author><author><persName><surname>Pvl</surname></persName></author></analytic><monogr><title level="j">Ew Heart J</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page" from="1284" to="1290"></biblScope><date type="published" when="1988"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysio-logic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome</title><author><persName><surname>Kerr Cr</surname></persName></author><author><persName><surname>Prystowsky</surname></persName></author><author><persName><surname>En</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Cook</surname></persName></author><author><persName><surname>Gallagher</surname></persName></author><author><persName><surname>Jj</surname></persName></author></analytic><monogr><title level="j">Ciuculation</title><imprint><biblScope unit="volume">65</biblScope><biblScope unit="page" from="869" to="878"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Clinical efficacy and electrophysiologic effects of intravenous and oral encain-ide in patients with accesxny atrioventricnlar pathways and supraventricnlar arrhythmias</title><author><persName><forename type="middle">H</forename><surname>Abdollah</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Brngada</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Green</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Wehr</surname></persName></author><author><persName><surname>Wellens Hjj</surname></persName></author><author><persName><surname>Panlussen</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol1984</title><imprint><biblScope unit="volume">54</biblScope><biblScope unit="page" from="5" to="549"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Encainide for treatment of supraventricnlar tachycardias associated with the Wolff-Parkinson-White syndrome</title><author><persName><surname>Markel Ml</surname></persName></author><author><persName><surname>Prystowsky En</surname></persName></author><author><persName><surname>Heger</surname></persName></author><author><persName><forename type="first">Miles</forename><forename type="middle">Wm</forename><surname>Jj</surname></persName></author><author><persName><forename type="middle">N</forename><surname>Fineberg</surname></persName></author><author><persName><surname>Dp</surname></persName></author></analytic><monogr><title level="j">Am .I Car&~</title><imprint><biblScope unit="volume">58</biblScope><biblScope unit="page">4148</biblScope><date type="published" when="1986"></date></imprint></monogr><note>suppl. C</note></biblStruct><biblStruct><analytic><title level="a" type="main">Clinical efficacy and electrophysiologic effects of encainide in pa-tients with Wolff-Parkinson-White syndrome</title><author><persName><surname>Prystows@ En</surname></persName></author><author><persName><forename type="first">Rikenberger</forename><forename type="middle">Rl</forename><surname>Klein Cj</surname></persName></author><author><persName><surname>Heger Jj</surname></persName></author><author><persName><surname>Naccarelli Gv</surname></persName></author><author><persName><surname>Dp</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">69</biblScope><biblScope unit="page" from="27" to="287"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Efficacy of pro-pafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up</title><author><persName><surname>Ludmer Pl</surname></persName></author><author><persName><surname>Mcgowan Ne</surname></persName></author><author><persName><forename type="middle">Em</forename><surname>Antman</surname></persName></author><author><persName><surname>Friedman</surname></persName></author></analytic><monogr><title level="j">JAm CoU Cardtil</title><imprint><biblScope unit="volume">9</biblScope><biblScope unit="page" from="1357" to="1363"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Kns</forename><forename type="middle">M T</forename><surname>Dubuc</surname></persName></author><author><persName><forename type="first">Lambert</forename><forename type="middle">Ma C</forename><surname>Campa</surname></persName></author><author><persName><forename type="first">Rosengarten</forename><forename type="middle">M</forename><surname>Shenasa</surname></persName></author></analytic><monogr><title level="j">Am Heart J</title><imprint><biblScope unit="volume">117</biblScope><biblScope unit="page" from="37" to="376"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electropharmacology of sotalol in pa-tients with Wolff-Parkinson-White syndrome</title><author><persName><forename type="first">Mitchell</forename><forename type="middle">Lb</forename><surname>Wyse Dc</surname></persName></author><author><persName><surname>Dti</surname></persName></author><author><persName><surname>Hj</surname></persName></author></analytic><monogr><title level="j">Ctiulafioa</title><imprint><biblScope unit="volume">76</biblScope><biblScope unit="page" from="810" to="818"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Sotalol in patients with Wolff-Parkinson-White syndrome</title><author><persName><surname>Knnze Kp</surname></persName></author><author><persName><forename type="middle">M</forename><surname>S&inter</surname></persName></author><author><persName><surname>Knck</surname></persName></author><author><persName><surname>Kh</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">75</biblScope><biblScope unit="page" from="10" to="5"></biblScope><date type="published" when="1987"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Protection against ventricular and atrial fibrillation by sotalol</title><author><persName><forename type="first">Beatrix</forename><forename type="middle">L Q</forename><surname>Timour-Char</surname></persName></author><author><persName><forename type="first">Lang</forename><forename type="middle">J M</forename><surname>Faucon</surname></persName></author></analytic><monogr><title level="j">Cardiovm Res</title><imprint><biblScope unit="volume">20</biblScope><biblScope unit="page" from="35" to="363"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wol&P&inson-White syndrome Side effects of long-term amiodarone therapy</title><author><persName><forename type="first">Ck</forename><surname>Field</surname></persName></author><author><persName><forename type="middle">K</forename><surname>Nademanee</surname></persName></author><author><persName><forename type="first">Weiss</forename><forename type="middle">W J</forename><surname>Stevenson</surname></persName></author><author><persName><forename type="middle">T</forename><surname>Klitzner</surname></persName></author><author><persName><surname>Singh</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Bn 5l Harris</surname></persName></author><author><persName><surname>Mckenna</surname></persName></author><author><persName><forename type="first">Rowland</forename><forename type="middle">E</forename><surname>Wj</surname></persName></author><author><persName><surname>Holt</surname></persName></author><author><persName><surname>Dw</surname></persName></author><author><persName><forename type="middle">Gca</forename><surname>Storey</surname></persName></author></analytic><monogr><title level="j">Am Hemi J Circulation</title><imprint><biblScope unit="volume">11567</biblScope><biblScope unit="page" from="102" to="10745"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000155 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000155 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6CE97C7DC3D05682871620BECA3DB2EB9D710005
|texte= Flecainide in the Wolff-Parkinson-White syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |